210 related articles for article (PubMed ID: 32556068)
21. Capillary-leak syndrome: an unrecognized early immune adverse effect of checkpoint-inhibitors treatment.
Percik R; Nethanel A; Liel Y
Immunotherapy; 2021 Jun; 13(8):653-659. PubMed ID: 33847145
[TBL] [Abstract][Full Text] [Related]
22. Checkpoint inhibitor myasthenia-like syndrome and myositis associated with extraocular muscle atrophy.
Ozarczuk TRA; Prentice DA; Kho LK; vanHeerden J
J Clin Neurosci; 2020 Jan; 71():271-272. PubMed ID: 31889642
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Outcome of Tofacitinib in Immune checkpoint Inhibitor Colitis.
Bishu S; Melia J; Sharfman W; Lao CD; Fecher LA; Higgins PDR
Gastroenterology; 2021 Feb; 160(3):932-934.e3. PubMed ID: 33096100
[No Abstract] [Full Text] [Related]
24. Severe cutaneous adverse reaction following COVID-19 vaccination and immunotherapy: a second hit?
Hussain K; Kawsar A; Weir J; Au L; Turajlic S; Larkin J; Fearfield L
Clin Exp Dermatol; 2022 Jan; 47(1):149-151. PubMed ID: 34260095
[No Abstract] [Full Text] [Related]
25. Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation.
Valenti-Azcarate R; Esparragosa Vazquez I; Toledano Illan C; Idoate Gastearena MA; Gállego Pérez-Larraya J
Neuromuscul Disord; 2020 Jan; 30(1):67-69. PubMed ID: 31839404
[TBL] [Abstract][Full Text] [Related]
26. Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: a case report and review of the literature.
Klepper EM; Robinson HN
Dermatol Online J; 2021 Sep; 27(9):. PubMed ID: 34755978
[TBL] [Abstract][Full Text] [Related]
27. SEVERE MULTIFOCAL PLACOID CHORIORETINITIS ASSOCIATED WITH IMMUNE CHECKPOINT INHIBITOR THERAPY.
Yu JJ; Everett L; Sassalos TM; Johnson MW
Retin Cases Brief Rep; 2024 Jul; 18(4):459-463. PubMed ID: 36913672
[TBL] [Abstract][Full Text] [Related]
28. First case of hemophagocytic lymphohistiocytosis secondary to cabozantinib with checkpoint inhibitors.
Azari AE; Stratton R; Singh A
Rheumatology (Oxford); 2021 May; 60(5):e167-e168. PubMed ID: 33280022
[No Abstract] [Full Text] [Related]
29. Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab.
Hantel A; Gabster B; Cheng JX; Golomb H; Gajewski TF
J Immunother Cancer; 2018 Jul; 6(1):73. PubMed ID: 30012206
[TBL] [Abstract][Full Text] [Related]
30. Recognizing encephalopathy in immune checkpoint inhibitor therapy: A single-center experience.
Wei D; Zhou DJ; Datta P; Taraschenko O
Cancer Med; 2021 May; 10(9):2978-2986. PubMed ID: 33660430
[TBL] [Abstract][Full Text] [Related]
31. Vitiligo expansion and extent correlate with durable response in anti-programmed death 1 antibody treatment for advanced melanoma: A multi-institutional retrospective study.
Matsuya T; Nakamura Y; Matsushita S; Tanaka R; Teramoto Y; Asami Y; Uehara J; Aoki M; Yamamura K; Nakamura Y; Fujisawa Y; Livingstone E; Zimmer L; Schadendorf D; Kagamu H; Fujimoto M; Honma M; Ishida-Yamamoto A; Araki R; Yamamoto A
J Dermatol; 2020 Jun; 47(6):629-635. PubMed ID: 32275100
[TBL] [Abstract][Full Text] [Related]
32. The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma.
Scott ES; Long GV; Guminski A; Clifton-Bligh RJ; Menzies AM; Tsang VH
Eur J Endocrinol; 2018 Feb; 178(2):173-180. PubMed ID: 29187509
[TBL] [Abstract][Full Text] [Related]
33. Long-term immune-related adverse events after discontinuation of immunotherapy.
Horisberger K; Portenkirchner C; Rickenbacher A; Biedermann L; Gubler C; Turina M
Immunotherapy; 2021 Jun; 13(9):735-740. PubMed ID: 33882697
[TBL] [Abstract][Full Text] [Related]
34. Successful treatment of immune checkpoint inhibitor-related periaortitis.
Bührer ED; Alberts IL; Christ L; Özdemir BC
Swiss Med Wkly; 2024 Feb; 154():3631. PubMed ID: 38579296
[TBL] [Abstract][Full Text] [Related]
35. Immune Checkpoint Inhibitor-Induced Ptosis in a Patient With Prostate Cancer.
Williams KJ; Allen RC
J Neuroophthalmol; 2021 Mar; 41(1):e71-e72. PubMed ID: 32235233
[No Abstract] [Full Text] [Related]
36. Management of immune-related hepatitis in patients being treated with checkpoint inhibitors for metastatic melanoma, a review and case series.
Tew A; Khoja L; Pallan L; Steven N
J Oncol Pharm Pract; 2023 Jul; 29(5):1163-1171. PubMed ID: 35607278
[TBL] [Abstract][Full Text] [Related]
37. Autoimmune polyradiculitis due to combination immunotherapy with ipilimumab and nivolumab for the treatment of metastatic melanoma.
Lasocki A; Smith K
J Clin Neurosci; 2020 Apr; 74():240-241. PubMed ID: 31983645
[TBL] [Abstract][Full Text] [Related]
38. Combination Therapy of Ipilimumab and Nivolumab-associated Toxic Epidermal Necrolysis (TEN) in a Patient With Metastatic Melanoma: A Case Report and Literature Review.
Logan IT; Zaman S; Hussein L; Perrett CM
J Immunother; 2020 Apr; 43(3):89-92. PubMed ID: 31651559
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of nivolumab in advanced melanoma: a drug review.
Specenier P
Expert Rev Pharmacoecon Outcomes Res; 2021 Feb; 21(1):13-28. PubMed ID: 33225752
[No Abstract] [Full Text] [Related]
40. Sicca syndrome following immune checkpoint inhibition.
Mavragani CP; Moutsopoulos HM
Clin Immunol; 2020 Aug; 217():108497. PubMed ID: 32531346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
